A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring

Recruiting now

Conditions studied: Familial Pancreatic Cancer, Familial Pancreatic Carcinoma, Hereditary Pancreatic Cancer, Hereditary Pancreatitis, Pancreas Cancer, Pancreas Neoplasm, Pancreas Adenocarcinoma, Pancreas Cyst, Pancreatic Neoplasms, Intraductal Papillary Mucinous Neoplasm

In brief

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an asymptomatic early phase, late diagnosis, and poor survival, particularly in individuals who develop disease outside the context of early-stage detection. Early detection strategies are currently limited to imaging-based surveillance (MRI and endoscopic ultrasound) in selected high-risk populations, but these approaches are invasive, costly, and suboptimal in sensitivity. The aim of this study is to evaluate circulating cell-free and exosome-bound microRNAs as non-invasive biomarkers of PDAC risk and disease biology

Key facts

Study ID

NCT07700992

Run by

Università Vita-Salute San Raffaele

People needed

600

Starts

2026-06-03

Expected to finish

2032-01-30

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult men or women aged ≥18 years at the time of plasma sample collection.
• Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to familial pancreatic cancer or hereditary pancreatic cancer syndrome
• Classification as at increased risk for pancreatic ductal adenocarcinoma (PDAC) due to the presence of one (or more) mucinous pancreatic cystic lesion(s).
• Availability of stored plasma samples collected as part of routine clinical care or surveillance and archived in the institutional biobank.
• Availability of relevant clinical and demographic data in institutional medical records sufficient to address study objectives.
• Prior provision of informed consent for biobanking and research use of biological samples and data

You may not qualify if…

• Absence or insufficient quality/quantity of stored plasma samples for laboratory analysis.
• Lack of clinical data required for cohort classification and/or outcome assessment.
• History of pancreatic surgery or interventional procedures prior to plasma sample collection.
• Concurrent active malignancy at the time of sample collection, other than non-melanoma skin cancer.
• Samples collected outside routine clinical care or not compliant with institutional biobanking and data protection policies.

Where it is running

• IRCCS San Raffaele Hospital — Milan, MI, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.